paid access
Analysis of access to treatment of patients with psoriatic arthritis within nationally founded treatment program B.35 “Treatment of active Psoriatic arthritis (PsA) (ICD-10 L 40.5, M 07.1, M 07.2, M 07.3)” in 2016–2021
, 1, 1
Affiliations- Department of Dermatology, Paediatric Dermatology and Oncology, Medical University of Lodz
paid access
Abstract
Introduction: Psoriatic arthritis (PsA), is a chronic disease affecting women and men in equal measure. It is characterised by a diverse course, usually progressive and severe in 20% of patients. The symptoms develop progressively. In almost 75% of patients, skin symptoms precede joint symptoms, while 10–15% experience simultaneous symptoms in both skin and joints. The disease is characterised by a highly fluctuating course, with periods of exacerbation and remission. Funding for the treatment of patients with psoriatic arthritis with biological drugs is guaranteed under the B.35 drug programme. The analysis of the performance of this programme is the aim of this work.
Material and methods: The statistical analysis was based on data published by the National Health Fund and the Ministry of Health.
Results: Between 2016 and 2021, 8 active substances were funded under the B.35 drug programme, 4 of which were added in the last 6 years. The number of patients increased by 2087. The largest group of patients received care from physicians in the Małopolskie Voivodeship. The most common active substance used under the B.35 drug programme was adalimumab, while the highest annual increase in patients treated under the programme was observed for the drug secukinumab. The value of contracts for drugs increased by PLN 15.7 million, while the value of contracts for programme operations increased by PLN 3.7 million. The number of providers implementing this drug programme has increased by one.
Conclusions: The B.35 drug programme is more substantial in terms of the number of patients treated and the value of funding than the B.47 (psoriasis) drug programme but smaller than the B.36 — ankylosing spondylitis (AS) drug programme implemented by rheumatologists. Virtually all drugs licensed for the treatment of moderate to severe psoriatic arthritis are currently reimbursed under the drug programme. Comparing epidemiological data in Poland and the number of patients in the drug programme, it should be pointed out that only about 1.8% of the total population of patients with PsA receives treatment. These very low values point to the need to further optimise the description of the drug programme or to transfer some drugs, for example, biosimilars, to outpatient health care.
Abstract
Introduction: Psoriatic arthritis (PsA), is a chronic disease affecting women and men in equal measure. It is characterised by a diverse course, usually progressive and severe in 20% of patients. The symptoms develop progressively. In almost 75% of patients, skin symptoms precede joint symptoms, while 10–15% experience simultaneous symptoms in both skin and joints. The disease is characterised by a highly fluctuating course, with periods of exacerbation and remission. Funding for the treatment of patients with psoriatic arthritis with biological drugs is guaranteed under the B.35 drug programme. The analysis of the performance of this programme is the aim of this work.
Material and methods: The statistical analysis was based on data published by the National Health Fund and the Ministry of Health.
Results: Between 2016 and 2021, 8 active substances were funded under the B.35 drug programme, 4 of which were added in the last 6 years. The number of patients increased by 2087. The largest group of patients received care from physicians in the Małopolskie Voivodeship. The most common active substance used under the B.35 drug programme was adalimumab, while the highest annual increase in patients treated under the programme was observed for the drug secukinumab. The value of contracts for drugs increased by PLN 15.7 million, while the value of contracts for programme operations increased by PLN 3.7 million. The number of providers implementing this drug programme has increased by one.
Conclusions: The B.35 drug programme is more substantial in terms of the number of patients treated and the value of funding than the B.47 (psoriasis) drug programme but smaller than the B.36 — ankylosing spondylitis (AS) drug programme implemented by rheumatologists. Virtually all drugs licensed for the treatment of moderate to severe psoriatic arthritis are currently reimbursed under the drug programme. Comparing epidemiological data in Poland and the number of patients in the drug programme, it should be pointed out that only about 1.8% of the total population of patients with PsA receives treatment. These very low values point to the need to further optimise the description of the drug programme or to transfer some drugs, for example, biosimilars, to outpatient health care.
Full Text:
Add to basket: 49.00 PLN
Keywords
psoriatic arthritis, biologicals, nationally founded treatment program
About this articleTitle
Analysis of access to treatment of patients with psoriatic arthritis within nationally founded treatment program B.35 “Treatment of active Psoriatic arthritis (PsA) (ICD-10 L 40.5, M 07.1, M 07.2, M 07.3)” in 2016–2021
Journal
Issue
Article type
Research paper
Pages
1-11
Published online
2023-02-17
Page views
2075
Article views/downloads
36
DOI
Bibliographic record
Forum Dermatologicum 2023;9(1):1-11.
Keywords
psoriatic arthritis
biologicals
nationally founded treatment program
Authors
Marcin Noweta
Joanna Narbutt
Aleksandra Lesiak
References (16)- Gajewski P. Interna Szczeklika, Podręcznik Chorób Wewnętrznych. Medycyna Praktyczna, Kraków 2018.
- Stanisławska-Biernat E, Świerkot J, Tłustochowicz W. Spondyloatropatie: Zalecenia postępowania diagnostycznego i terapeutycznego. Reumatologia 2012; 50. ; 2: 93–102.
- Veale D, Rogers S, Fitzgerald O. Classification of clinical subsets in psoriatic arthritis. Br J Rheumatol. 1994; 33(2): 133–138.
- https://www.who.int/standards/classifications/classification-of-diseases.
- American College of Rheumatology/National Psoriasis Foundation. merican College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis & Rheumatology. 2019; 71(1): 5–22.
- Dz. U. 2011 Nr 122 poz. 696; Ustawa z dnia 12 maja 2011 r. o refundacji leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych.
- ZARZĄDZENIE Nr 162/2020/DGL PREZESA NARODOWEGO FUNDUSZU ZDROWIA z dnia 16 października 2020 r. w sprawie określenia warunków zawierania i realizacji umów w rodzaju leczenie szpitalne w zakresie programy lekowe.
- ttps://www.nfz.gov.pl/o-nfz/informator-o-zawartych-umowach/.
- UCHWAŁA Nr 3/2022/IV RADY NARODOWEGO FUNDUSZU ZDROWIA z dnia 16 marca 2022 r. w sprawie przyjęcia okresowego sprawozdania z działalności Narodowego Funduszu Zdrowia za IV kwartał 2021 r.
- Karmacharya P, Wright K, Achenbach SJ, et al. Diagnostic delay in psoriatic arthritis: a population-based study. J Rheumatol. 2021; 48(9): 1410–1416.
- Haroon M, Gallagher P, FitzGerald O. Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritis. Ann Rheum Dis. 2015; 74(6): 1045–1050.
- Zhao SS, Pittam B, Harrison NL, et al. Diagnostic delay in axial spondyloarthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2021; 60(4): 1620–1628.
- Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised, placebo-controlled trial (the GO-REVEAL study). Ann Rheum Dis. 2014; 73(9): 1689–1694.
- van de Kerkhof PCM, Reich K, Kavanaugh A, et al. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. J Eur Acad Dermatol Venereol. 2015; 29(10): 2002–2010.
- Inotai A, Tomek D, Niewada M, et al. Identifying patient access barriers for tumor necrosis factor alpha inhibitor treatments in rheumatoid arthritis in five central eastern european countries. Front Pharmacol. 2020; 11: 845.
- Obwieszczeniem Ministra Zdrowia z dnia 21 grudnia 2020 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 stycznia 2021 r.
